KALA BIO sets Nov. 3, 2026 shareholder meeting

KALA BIO set its 2026 annual meeting for November 3 and established September 19, 2026 as the deadline for shareholder proposals and director nominations.

Rhea-AI Filing Summary

KALA BIO, Inc. (KALA) announced that its Board of Directors set November 3, 2026 as the date of the next annual meeting of stockholders. Additional information on the exact time, location and agenda items will be provided in the company’s proxy statement.

Because this date is more than 30 days earlier than the prior year’s annual meeting, stockholder proposals for inclusion in proxy materials under Rule 14a-8 must be received at the company’s principal executive offices by September 19, 2026. Stockholders nominating directors or proposing other business under the company’s Third Amended and Restated By-Laws must also deliver notice by September 19, 2026 and comply with all requirements in the By-Laws and applicable law.

8-K Event Classification

2 items: 5.08, 8.01

2 items

Item 5.08 Shareholder Director Nominations Governance

Shareholder nominations for board of directors under proxy access rules. Rarely used -- the underlying SEC rule was vacated.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Annual meeting date: November 3, 2026 Rule 14a-8 proposal deadline: September 19, 2026 By-Law notice deadline: September 19, 2026 +1 more

4 metrics

Annual meeting date November 3, 2026 Date set by the Board of Directors for the next annual meeting of stockholders

Rule 14a-8 proposal deadline September 19, 2026 Deadline for stockholder proposals for inclusion in proxy materials

By-Law notice deadline September 19, 2026 Deadline to submit director nominations or other business under the By-Laws

Principal executive offices ZIP code 02476 ZIP code for 1167 Massachusetts Avenue, Arlington, Massachusetts, the company’s principal executive offices

Key Terms

Rule 14a-8, proxy materials, Third Amended and Restated By-Laws, public announcement, +1 more

5 terms

Rule 14a-8 regulatory

"stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act"

Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.

proxy materials regulatory

"for inclusion in the Company’s proxy materials relating to the Annual Meeting"

Proxy materials are the packet of documents sent to shareholders that explain items to be voted on at a company meeting and include the actual ballot or instructions for casting a vote. Think of them as a voting packet that lays out who’s running the company, major proposals (like pay, mergers, or board changes), and arguments for and against each item. Investors care because those votes shape corporate direction, affect risk and future profits, and can influence share value.

Third Amended and Restated By-Laws regulatory

"must also comply with the Company’s Third Amended and Restated By-Laws"

public announcement regulatory

"the 10th day following the day on which public announcement of the date"

The Nasdaq Capital Market market

"Common Stock, $0.001 par value per share ... The Nasdaq Capital Market"

A tier of the Nasdaq stock exchange that hosts smaller or early-stage public companies that meet defined listing standards for size, share price and governance. Think of it as a particular shelf in a store for emerging brands: it gives investors a centralized place to find and trade these stocks while signaling that the companies meet basic regulatory and financial rules. Investors watch it for growth opportunities and higher volatility compared with larger markets.

FAQ

When is KALA (KALA BIO, Inc.) holding its next annual meeting of stockholders?

The Board of KALA BIO, Inc. set the next annual meeting of stockholders for November 3, 2026. The company will provide the exact time, location and matters to be voted on in its proxy statement for the annual meeting.

What is the deadline for KALA stockholder proposals under Rule 14a-8 for the 2026 annual meeting?

To be included in KALA BIO, Inc.’s proxy materials under Rule 14a-8, stockholder proposals must be received by the company’s Secretary at its principal executive offices by September 19, 2026, which the company determined is a reasonable time before proxy materials are printed and sent.

What is the deadline to nominate directors or propose other business at KALA’s 2026 annual meeting under the By-Laws?

Stockholders wishing to nominate a director or propose other business under KALA BIO, Inc.’s Third Amended and Restated By-Laws must deliver notice to the company’s Secretary by September 19, 2026, in accordance with By-Laws Sections 1.10(b) and 1.11(b).

Where should KALA BIO stockholders send proposals or director nominations for the 2026 annual meeting?

Proposals and nominations must be sent to the Secretary of KALA BIO, Inc. at its principal executive offices: 1167 Massachusetts Avenue, Arlington, Massachusetts 02476, and must meet Rule 14a-8, the By-Laws, and all applicable legal requirements.

Why did KALA BIO set special deadlines for stockholder proposals for the 2026 meeting?

KALA BIO set special deadlines because the November 3, 2026 annual meeting date will be advanced by more than 30 days from the first anniversary of the prior annual meeting. As a result, the company established September 19, 2026 as the cut-off for Rule 14a-8 and By-Law notices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 05:06 PM Accepted by SEC EDGAR 09/09/2026 - 05:06 PM Learn about SEC filing dates

false 0001479419 0001479419 2026-09-09 2026-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2026

KALA BIO, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-38150		27-0604595
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1167 Massachusetts Avenue Arlington, MA		02476
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 996-5252

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		KALA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.08 Shareholder Director Nominations.

To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.

Item 8.01 Other Events.

On September 9, 2026, the Board of Directors of KALA BIO, Inc. (the “Company”) established November 3, 2026 as the date of the Company’s next annual meeting of stockholders (the “Annual Meeting”). The Company plans to publish additional details regarding the exact time, location and matters to be voted on at the Annual Meeting in the Company’s proxy statement for the Annual Meeting.

Because the date of the Annual Meeting will change by more than 30 calendar days from the anniversary date of the Company’s last annual meeting of stockholders, the Company has set a deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (“Rule 14a-8”) for inclusion in the Company’s proxy materials relating to the Annual Meeting. In order for a proposal under Rule 14a-8 to be timely, it must be received by the Company’s Secretary at the principal executive offices of the Company by September 19, 2026, which the Company has determined to be a reasonable time before the Company’s proxy materials are due to be printed and sent. Such proposals must also comply with the Company’s Third Amended and Restated By-Laws (the “By-Laws”) and the rules of the Securities and Exchange Commission regarding the inclusion of stockholder proposals in proxy materials, and any such proposal may be omitted if not in compliance with applicable requirements.

The address of the Company’s principal executive offices is 1167 Massachusetts Avenue, Arlington, Massachusetts 02476.

Stockholders wishing to nominate a director or propose matters to be considered at the Annual Meeting in the manner contemplated by the By-Laws must submit timely notice to the Company in order for such matters to be considered at the Annual Meeting. Because the date of the Annual Meeting will be advanced by more than 30 days from the first anniversary of the Company’s last annual meeting of stockholders, in accordance with Sections 1.10(b) and 1.11(b) of the By-Laws, such notice must be received by the Company’s Secretary at the address above by September 19, 2026 (which is the 10^th day following the day on which public announcement of the date of the Annual Meeting was first made by the Company). Such proposals must also comply with all other requirements set forth in the By-Laws and other applicable laws.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KALA BIO, INC.
Date: September 9, 2026	By:	/s/ Avi Minkowitz
		Avi Minkowitz
		Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB